Skip to main content

Sirolimus protein-bound Disease Interactions

There are 4 disease interactions with sirolimus protein-bound.

Moderate

Sirolimus albumin bound (applies to sirolimus protein-bound) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of sirolimus albumin-bound should be avoided in patients with severe hepatic impairment. Closely monitor patients with mild and moderate impairment for increased liver toxicity. Dosage should be reduced in these patients.

References

  1. (2022) "Product Information. Fyarro (sirolimus protein-bound)." Aadi Bioscience, Inc.
Moderate

Sirolimus albumin-bound (applies to sirolimus protein-bound) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Sirolimus albumin-bound can cause hyperglycemia. Fasting serum glucose should be monitored prior to starting treatment, and periodically during treatment in diabetic patients. Caution is advised.

References

  1. (2022) "Product Information. Fyarro (sirolimus protein-bound)." Aadi Bioscience, Inc.
Moderate

Sirolimus albumin-bound (applies to sirolimus protein-bound) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The effect of severe renal impairment on the pharmacokinetics of sirolimus albumin-bound is unknown. Caution and close monitoring is advised if using in these patients.

References

  1. (2022) "Product Information. Fyarro (sirolimus protein-bound)." Aadi Bioscience, Inc.
Moderate

Sirolimus albumin-bound (applies to sirolimus protein-bound) vaccination

Moderate Potential Hazard, Moderate plausibility.

Immunizations during treatment with sirolimus albumin-bound may be ineffective. Immunization with live vaccines is not recommended during treatment and close contact with those who have received live vaccines should be avoided. Required immunizations should be updated according to immunization guidelines prior to initiating treatment, if possible. The interval between live vaccinations and treatment initiation should be in accordance with current vaccination guidelines for patients on immunosuppressive therapies.

References

  1. (2022) "Product Information. Fyarro (sirolimus protein-bound)." Aadi Bioscience, Inc.

Sirolimus protein-bound drug interactions

There are 367 drug interactions with sirolimus protein-bound.

Sirolimus protein-bound alcohol/food interactions

There is 1 alcohol/food interaction with sirolimus protein-bound.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer